Document is current
Any future updates will be listed below
-
Authors
Goel, Anshita
Ward, Douglas G.
Noyvert, Boris
Yu, Minghao
Gordon, Naheema S.
Abbotts, Ben
Colbourne, John K.
Kissane, Stephen
James, Nicholas D.
Zeegers, Maurice P.
Cheng, Kar Keung
Cazier, Jean-Baptiste
Whalley, Celina M.
Beggs, Andrew D.
Palles, Claire
Arnold, Roland
Bryan, Richard T. https://orcid.org/0000-0003-2853-4293
-
Funding
Funding for this research was provided by:
Cancer Research UK (C1343/A5738)
- License Information
-
More Information
Article History
Received: 21 December 2021
Accepted: 5 May 2022
First Online: 3 June 2022
Declarations
:
: Participants gave written informed consent for enrolment into the present study based upon initial cystoscopic findings suggestive of primary Bladder Cancer (UK national research ethics approval 06/MRE04/65, East Midlands - Derby Research Ethics Committee). The research was undertaken in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments.
: Not applicable.
: ND James has contributed to the advisory boards for Merck USA and Pierre Fabre. RT Bryan has contributed to the advisory boards for Olympus Medical Systems, Janssen and Nonacus Limited and has undertaken research funded by UroGen Pharma, QED Therapeutics and Janssen. DG Ward has contributed to the advisory boards for Nonacus Limited. The remaining authors declare that they have no competing interests.
